Galecto ditches high doses in phase II trial
An independent data safety monitoring board recommends that Galecto ditches the highest dose of the firm's drug GB0139 in a phase 2b study against idiopathic pulmonary fibrosis.
BY ELIZABETH MØNSTED JOHANSEN & ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
After an independent data safety monitoring board has looked through preliminary data from Galecto's phase IIb study of idiopathic pulmonary fibrosis (IPF), the company has been forced to rearrange the trial on the basis of the monitoring board's recommendations, according to a press statement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
